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Abstract
Several recent reports have described osteonecrosis of the jaws
(ONJ) associated with the use of bisphosphonates. Rheuma-
tologists treating bone diseases with bisphosphonate need,
therefore, to be aware of this potential risk and plan the
prophylaxis, early diagnosis and prevention of potential conse-
quences. We review the literature on this newly described
complication, with particular focus on systemic and local pre-
disposing pathologies, preventive measures suggested before and
during therapy with bisphosphonates, and the most frequent
clinical presentation of the oral lesions. The expert panel
recommendations for the management of care of patients who
develop ONJ are summarized.
Introduction
Bisphosphonates are becoming increasingly important in the
treatment of metabolic and oncological diseases involving the
skeleton [1-3]. These carbon-substituted pyrophosphate
analogs are potent inhibitors of osteoclast-mediated bone
resorption. The most recent nitrogen-containing bisphospho-
nates, or aminobisphosphonates, have greater potency and
better selectivity; the most commonly used aminobisphos-
phonates include alendronate, risedronate, ibandronate,
pamidronate and zoledronate. Alendronate, risedronate and
ibandronate are used for the prevention and treatment of
osteoporosis, while pamidronate and zoledronate have an
essential role in the prevention of bone complications and the
treatment of severe hypercalcemia associated with multiple
myeloma or bone metastases from breast and prostate
cancers [2,3].
Generally, these drugs are well tolerated, rarely inducing
clinically significant side effects: gastrointestinal symptoms
for oral bisphosphonates (alendronate and risedronate);
elevated serum creatinine, transient low-grade fever,
arthralgias and increased bone pain for the injectable drugs
(pamidronate and zoledronate) [4]. However, recent reports
have described osteonecrosis of the jaw bones (ONJ) as a
potentially serious complication of the long-term use of these
drugs [5-7]. In this condition the bone tissue in the jaw fails to
heal often after minor trauma, such as a tooth extraction,
leaving the bone exposed.
To date, the majority of cases of bisphosphonate-associated
ONJ have been reported in the oral surgical or oncological
literature. This complication has been mainly reported in
patients receiving intravenous pamidronate and/or
zoledronate for multiple myeloma and bone metastases from
breast cancer. However, some considerations suggest that
increased awareness about this problem among rheuma-
tologists might be useful for informing patients and for
preventing this severe localized necrosis.
First, an increasing number of cases of bisphosphonate-
associated ONJ have been reported in patients taking an oral
bisphosphonate (alendronate or risedronate) for osteoporosis
or Paget’s disease [7-13]. Second, zoledronate, the most
potent aminobisphosphonate and the one most frequently
associated with ONJ, has also been recently proposed for
Paget’s disease [14,15] or osteoporosis [16]. Third, even
though at present bisphosphonate-associated ONJ seems to
be a rare bisphosphonate-induced complication, the number
of cases described has risen in the past three years. This may
be due to our increased awareness about ONJ but a
correlation with the total dose of bisphosphonate accumu-
lated in the bone has been suggested [8]; in both cases the
incidence will rise further in the next few years. Finally, since
no effective therapy for bisphosphonate-associated ONJ has
yet been established, it is vital to do everything possible to
prevent it. Rheumatologists using bisphosphonate to treat
bone diseases need to be aware of the potential risk of their
patients developing ONJ.
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Clinical features
The most widespread clinical picture heralding the onset of
bisphosphonate-associated ONJ is failure to heal, or slow
healing, of bone after extraction of a tooth or other local oral
surgery (70% to 80% of cases) [7,9,17,18]. In the early
stages there is no radiological evidence and the patient often
has no symptoms; pain usually indicates a superimposed
infection on the exposed bone.
In 25% to 40% of cases ONJ arises spontaneously, not
related to any particular trauma [9,18]. In these cases the
most frequent initial symptom is an unpleasant sensation in
the mouth (numbness, paresthesia and burning sensation),
with gradual changes to the mucosa, progressing to ulcers
that are sluggish to heal. Pain may be strong, and is usually
caused – as we said above – by super-infection of the
necrotic bone, due to the oral bacterial flora. These signs and
symptoms may precede the clinically evident onset of ONJ,
and it is essential to recognize them so as to take all possible
preventive measures (see below). ONJ is a progressive
disorder causing extensive exposure of the maxillary or
mandibular bone, with sequestration.
The mandible and maxilla are normally the only bones
involved in bisphosphonate-induced osteonecrosis, the most
common site of exposure being the mandible in the area of
the molars (about 70% of cases), followed by the posterior
maxilla (about 30%); only few cases occur simultaneously in
the mandible and maxilla [9]. Involvement of the maxilla is a
notable difference between bisphosphonate-related ONJ and
osteoradionecrosis, a form of osteonecrosis secondary to
radiotherapy for head and neck cancer that affects the
mandible in 95% of cases [19].
Before starting bisphosphonate therapy, a scrupulous search
for systemic and local predisposing factors is essential. The
most important predisposing factors for the development of
bisphosphonate-assciated ONJ are the type and total dose of
bisphosphonate, but other predisposing or precipitating
factors have been suggested: a diagnosis of cancer, a history
of trauma or dental surgery, poor oral health, dental infections
and the presence of mandibular tori [9,20-23]. Cortico-
steroids and chemotherapy have been suggested to be
associated with additional risk for ONJ but their specific
contribution should be addressed in properly designed
studies [21-23]. Of particular interest in terms of prevention
is the knowledge that invasive dental procedures, such as
removal of a tooth, periodontal surgery and dental implant
placement, have been related to ONJ in more than 70% of
cases [7,9,17,18].
Epidemiology
The first extensive reviews of bisphosphonate-related ONJ
were published in 2003 by Marx, with 36 cases [6]. Since
then, a study of 63 cases by Ruggiero and colleagues [7],
and others by Bagan and colleagues (10 cases) [24] and
Marx and colleagues (119 cases) [9], together with many
small series and case reports, have provided additional
information on the features of ONJ [8,10,11,13,17,18,25-38].
The complication was never encountered in clinical trials prior
to marketing pamidronate and zoledronate. In 2004 Novartis,
the manufacturer of both these drugs, issued post-marketing
guidelines regarding ONJ [39].
Although ONJ is considered an uncommon bisphosphonate-
induced complication, a recent worldwide web-based survey
evaluating its incidence in 1,203 patients receiving
intravenous bisphosphonates for myeloma (904 patients) or
breast cancer (299 patients) found definite or suspected
ONJ in 12.8% of myeloma patients and 12% with breast
cancer [22]. In these patients, after 36 months of bisphos-
phonate treatment, the estimated incidence of ONJ was 10%
among patients receiving zoledronate and 4% among
patients receiving pamidronate. The risk of developing ONJ
for patients taking alendronate, the most commonly pre-
scribed oral bisphosphonate, has been estimated to occur in
approximately 0.7 per 100,000 persons per years’ exposure
[40]; on the other hand, the incidence of ONJ for risedronate
and ibandronate cannot yet be quantified because too few
cases have been reported (12 cases for risedronate and one
for ibandronate) [40]. The duration of bisphosphonate therapy
was one of the major risk factors. Bamias and colleagues
[21] and Durie and colleagues [22] reported that patients
treated with a potent bisphosphonate for more than 12 months
were at highest risk of ONJ; the incidence rose with exposure
to the drugs.
Between 1998 and 2004 the Research on Adverse Drug
Events and Reports (RADAR) investigators identified 561
cases of ONJ in cancer patients taking zoledronate [41]; 126
additional cases of zoledronate-related ONJ have been
reported in the literature from 2005 until now [8-10,12,13,17,
18,24-33,35,36]. From 2003 until now (March 2006) another
261 cases of ONJ have been described in the literature, 141
of them receiving only pamidronate [6-13,17,18,24,26,31,33-
38], 101 pamidronate and zoledronate [6,7,9,10,12,13,17,
18,21,24,25,30-33,36], 21 aledronate [7-13], 1 risedronate
[7] and 4 combined therapy (1 alendronate, pamidronate and
zoledronate; 1 zoledronate and ibandronate; 1 alendronate
and zoledronate) [7,21,27].
It is still not clear which patients are at greatest risk of ONJ.
The complication has been mostly reported in cancer patients
treated with intravenous bisphosphonate. Therefore,
malignant diseases and a history of systemic chemotherapy
are considered the most significant comorbidities. However,
patients with ONJ unrelated to cancer have been reported
too: 19 patients with osteoporosis (17 receiving alendronate,
1 risedronate and 1 alendronate and zoledronate) [7-10,12,13]
and 9 patients with Paget’s disease of bone (4 receiving
alendronate, 4 pamidronate, 1 pamidronate and alendronate)
[8,11,12]. However, this is probably an underestimation ofPage 3 of 6
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the cases of ONJ associated with oral bisphosphonate. In
fact, in a recent review from the American Dental Association
[40] the total number of reported cases of possible ONJ
associated with oral bisphosphonates was 170 worldwide for
alendronate, 12 for risedronate and 1 for ibandronate.
Pathogenesis
Although the specific causal relationship has yet to be
established, the correlation between bisphosphonate therapy
and osteonecrosis appears strong. The specific mechanism
is not known but several pathogenetic factors seem to be
operative. Bisphosphonates prevent bone resorption by
inhibiting osteoclastic activity through different mechanisms:
inhibition of osteoclast development from monocytes [42],
increased osteoclast apoptosis [42], prevention of osteoclast
development and recruitment from bone marrow precursors
[43], stimulation of osteoclast inhibitory factor [44], and
reduction of osteoclast activity through an effect on the cell
cytoskeleton [45]. In addition, anti-angiogenetic properties
have been recently described for these drugs [46,47]. The
final result is a profound suppression of bone turnover and,
with time, a reduction or cessation of bone remodeling. This
brittle bone becomes unable to repair the physiological
microfractures that are caused daily in the jaws by
masticatory forces [9].
The particular location of bisphosphonate-induced osteo-
necrosis in the oral cavity may be attributable to the exposure
of these bone structures to the environment through the
gingival sulcus, which may facilitate bone infection and
progression to osteomyelitis [6,9,20,48]. The particular
structures of the oral cavity may explain why a large
proportion of cases are associated with tooth extractions or
other invasive dental procedures, when the risk of infections
as well as the need for bone repair and remodeling are
increased. Other pathogenetic factors may include conco-
mitant therapy and/or associated pathologies. The histo-
logical examination of bone, usually performed to exclude
metastatic bone disease, revealed necrotic bone with
inflammatory changes and bacterial superinfection [7,17,32].
The realization that ONJ could be the product of the loss of
osteoclastic bone remodeling and renewal in the presence of
physiological stress, local trauma or tooth infections offers
some indications on strategies for preventing it.
Prevention and therapy
We are not yet able to predict which patients are prone to
ONJ and at present there is no definite treatment for this
complication. This means preventive measures are of
paramount importance.
Recommendations for the prevention, diagnosis and
treatment of ONJ in cancer patients receiving intravenous
bisphosphonate therapy were developed by an expert panel
assembled by Novartis [49] and then by the American
Academy of Oral Medicine [20] and the American Academy
of Oral and Maxillofacial Pathology [23].
Of particular relevance for rheumatologists are the recently
developed expert panel recommendations for dental
management of patients receiving oral bisphosphonate
therapy [40]. The rheumatologist should inform the patient of
the usefulness of bisphosphonate therapy for the prevention
and treatment of osteoporosis or Paget’s disease of bone. At
the same time the patient needs to be aware of the potential
but very low risk of ONJ and its possible prevention
(Figure 1). A screening oral evaluation and history for local or
systemic risk factors for ONJ should be carried out by the
rheumatologist, or by the dentist if needed, before therapy
with bisphosphonate or as soon as possible after beginning
therapy. Any tooth extraction or surgical procedures should
be completed before bisphosphonate therapy with enough
time allowed for healing. The risk-benefit profile for each
individual patient should be considered before starting long-
term bisphosphonate therapy, and if there are any systemic or
local risk factors for ONJ (see above) an alternative therapy
should be considered, at least when possible, such as for
post-menopausal osteoporosis: estrogens, raloxifene,
strontium ranelate, teriparatide (reviewed in [50]). Further-
more, clodronate, an orally or parenterally administered first-
generation bisphosphonate, widely used in Europe with no
reports of associated osteonecrosis, should also be
considered [51].
Since the elimination of all potential sites of infection is the
primary objective [20], patients already receiving bisphos-
phonates must be informed of the best ways to maximize oral
hygiene, and regular dental inspections of oral health should
be scheduled. Since ONJ is more commonly associated with
dental procedures that traumatize bone, in these patients
endodontic therapy is preferred to tooth extraction and
invasive periodontal procedures or dental implant placement
should be avoided [20,40]. If these procedures cannot be
postponed, the rheumatologist must give the dentist or
maxillo-facial surgeon clear information on the patient’s
bisphosphonate therapy, so as to plan the dental treatment to
take it into full account and implement preventive measures to
avoid ONJ. At the same time, the patient should again be
informed about the potential but very small risk of developing
ONJ.
The onset of ONJ calls for immediate contact with the dental
specialist to agree on a course of action. As we said, there is
no definite therapy so complete resolution is usually not
possible. However, some therapeutic approaches have been
proposed, at least to restrict the necrotic area [9,20,31]. The
goals in a patient with ONJ are, of course, to relieve the pain,
but primarily to control secondary infection in the necrotic
area; this means abstaining – as far as possible – from dental
surgery so as not to enlarge it. Daily topical antimicrobial or
anti-inflammatory agents (for example, chlorhexidine gluco-
Available online http://arthritis-research.com/content/8/5/219nate rinses three to four times a day) are recommended. If
local infection is suspected, or confirmed by culture,
aggressive systemic antibiotics should be started, ideally –
unless the antibiotic sensitivity test indicates otherwise – with
penicillin-type antibiotics or doxycycline in penicillin-allergic
patients [9,20,31].
Unlike in radio-osteonecrosis, hyperbaric oxygen has not
given encouraging results in ONJ patients [7,9,20]. The utility
of stopping the bisphosphonates has not been proved either.
The long bioavailability and systemic uptake of the amino-
bisphosphonates [52] seems to make it pointless to withdraw
them once a patient clearly has ONJ [9,17,20,29]. However,
it has been suggested that it might be useful, when feasible,
to stop the drugs for several months in patients who
absolutely require local oral surgery [12,26,34,36].
Conclusion
ONJ is an emerging problem in patients taking long-term
bisphosphonate therapy. Even if the use of zoledronate
and/or pamidronate in cancer patients is a major risk factor
for ONJ, an increasing number of cases of ONJ in patients
taking oral bisphosphonate (alendronate, risedronate or
ibandronate) for osteoporosis or Pagets’ disease have been
described. Even if the number of cases of ONJ in patients
taking oral bisphosphonates are still rare compared to the
total exposure, rheumatologists treating bone diseases with
bisphosphonates need to be aware there is a small risk their
patients may develop this new complication, allowing for
prophylaxis, early diagnosis and prevention of potential
consequences. The benefit/risk of bisphosphonate therapy
should be individually discussed and, when necessary and
possible, alternative therapy for postmenopausal osteo-
porosis should be considered.
The need for the patient to be dentally fit and to maintain this
state forever should be part of the informed consent for
bisphosphonate treatment.
If until now it has been uncommon or unnecessary for
rheumatologists to ask about dental problems of their
patients, this new bisphosphonate-associated complication
highlights the need for this to change.
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